Top Page
Biosyent
(RX)
Biosyent (RX) vs. iShares MSCI Canada ETF (EWC)
Biosyent Business Overview & Revenue Model
Biosyent Earnings Call Summary
Biosyent Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 34.51M | 31.59M | 27.93M | 28.62M | 22.33M | 21.42M | Gross Profit |
| 27.17M | 25.60M | 22.86M | 22.64M | 17.42M | 16.65M | EBIT |
| 8.26M | 7.47M | 6.98M | 8.18M | 5.03M | 5.39M | EBITDA |
| 9.92M | 9.06M | 7.96M | 8.92M | 5.84M | 6.19M | Net Income Common Stockholders |
| 7.11M | 6.46M | 5.46M | 6.28M | 3.80M | 4.37M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 24.43M | 26.19M | 28.70M | 28.21M | 25.58M | 21.97M | Total Assets |
| 31.19M | 41.53M | 40.49M | 37.17M | 33.57M | 30.97M | Total Debt |
| 0.00 | 1.22M | 1.40M | 1.56M | 1.71M | 1.85M | Net Debt |
| -16.83M | -6.76M | -6.47M | -16.48M | -18.58M | -11.59M | Total Liabilities |
| 3.58M | 6.77M | 7.12M | 5.61M | 6.78M | 5.17M | Stockholders Equity |
| 27.61M | 34.76M | 33.36M | 31.55M | 26.80M | 25.79M |
| Cash Flow | Free Cash Flow | ||||
| -87.30K | 4.88M | 4.43M | 4.58M | 6.72M | 4.04M | Operating Cash Flow |
| 7.19M | 5.05M | 4.95M | 4.67M | 6.89M | 4.77M | Investing Cash Flow |
| 1.02M | 883.85K | -10.79M | -4.84M | 3.39M | -1.68M | Financing Cash Flow |
| -4.92M | -5.78M | -4.37M | -2.08M | -3.37M | -6.39M |
Biosyent Technical Analysis
Biosyent Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | C$137.08M | 17.46 | 22.17% | 1.59% | 16.55% | 14.70% | |
71 Outperform | C$91.61M | 14.26 | 11.27% | ― | -3.82% | -50.36% | |
60 Neutral | C$155.64M | ― | -23.05% | ― | -3.73% | 32.70% | |
58 Neutral | $161.85M | ― | ― | 16.23% | 85.76% | ||
55 Neutral | C$8.90M | ― | -18.52% | ― | 1.14% | -36.66% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
21 Underperform | C$663.17K | ― | 43.02% | ― | 129.21% | 26.79% |
Biosyent Corporate Events
BioSyent Inc. has announced a quarterly dividend of $0.05 per common share for the second quarter of 2025, payable on June 13, 2025, to shareholders of record as of May 30, 2025. This dividend is consistent with the first quarter’s dividend and is classified as an ‘eligible dividend’ for Canadian tax purposes. The announcement underscores BioSyent’s ongoing commitment to providing shareholder value and reflects its stable financial performance.
The most recent analyst rating on (TSE:RX) stock is a Buy with a C$11.75 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.
BioSyent Inc. reported strong financial results for the first quarter of 2025, with total company sales increasing by 42% compared to the first quarter of 2024. The company saw significant growth in its Canadian and international pharmaceutical sales, as well as its legacy business. Notably, the FeraMAX Pd product line continued to lead in the Canadian market for iron health, and the Tibelia product showed substantial growth following the acquisition of global product rights. Despite uncertainties in international trade, BioSyent remains focused on long-term growth and portfolio diversification. Additionally, the company announced the election of Mr. Prakash Gowd to its Board of Directors, succeeding Mr. Larry Andrews.
The most recent analyst rating on (TSE:RX) stock is a Buy with a C$11.75 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.
BioSyent Inc. announced it will release its financial results for the first quarter of 2025 on May 15, 2025, after market hours. The results will be accompanied by a presentation from the company’s President and CEO, René Goehrum, available on their website. This announcement could provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder interests.
BioSyent Inc. announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto, where CEO René Goehrum will present an overview of the company’s business and activities. This event provides an opportunity for BioSyent to engage with investors and potentially strengthen its market position by showcasing its growth-oriented strategies and innovative product offerings.
BioSyent Inc. has announced its participation in the Planet MicroCap Showcase: VEGAS 2025 investor conference in Las Vegas, where President and CEO René Goehrum will present and meet with investors. This participation highlights BioSyent’s active engagement with the investment community, potentially enhancing its market visibility and investor relations.
BioSyent Inc. announced that its President and CEO, René Goehrum, will present at the LD Micro Invitational XV Conference in New York City on April 10, 2025. This presentation and subsequent one-on-one meetings with investors highlight BioSyent’s proactive approach to engaging with stakeholders and promoting its growth-oriented pharmaceutical business.
BioSyent Inc. announced that its FeraMAX® brand has been named the #1 recommended iron supplement in Canada for the tenth consecutive year by pharmacists and physicians. This recognition underscores the brand’s leadership in iron health and its commitment to expanding its range of products to treat and prevent iron deficiency across all life stages. The recognition is based on a national survey that highlights the role of healthcare professionals in recommending over-the-counter products, reinforcing BioSyent’s strong market positioning and trust among Canadian healthcare providers.
BioSyent Inc. has announced the approval of a grant of 56,767 Restricted Share Units (RSUs) to certain directors, officers, management, and employees as part of its Restricted Share Unit Plan. These RSUs will fully vest within three years, potentially enhancing employee retention and aligning their interests with the company’s growth objectives. This move reflects BioSyent’s commitment to rewarding its team and could positively impact its operations by motivating key personnel.
BioSyent Inc. reported strong financial results for the fourth quarter and full year 2024, with significant growth in Canadian pharmaceutical sales and a notable increase in EBITDA and net income. The acquisition of global rights to Tibelia® (tibolone) and the transition of its distribution to BioSyent’s structure are expected to diversify revenue streams and enhance profitability. The company also maintained its commitment to shareholders by returning $7.3 million through dividends and share buybacks, marking its 15th consecutive year of profitability.